title: Estracyt therapy of advanced prostatic cancer with special reference to control of therapy with cytology and DNA cytophotometry.
abstract: 81 patients with advanced prostate carcinoma, mainly estrogen resistant, were treated with Estracyt. After a pilot study had shown encouraging results in the first 39 cases, the preparation was used on a further 42 patients and for 38 of these its therapeutic effectiveness was evaluated according to internationally defined clinical criteria. In this way, an objective therapeutic success quota of 55% of all 38 patients was obtained. In the group with estrogen-resistant tumors the value was still found to be as high as 35%. These clinical results were confirmed by cytomorphological control of the degree of regression of the tumor effected by the therapy, and also by single-cell cytophotometric analysis of the DNA content of various prostate carcinomas treated wtih Estracyt.
mesh_terms: D001707:Biopsy, Needle; D004273:DNA, Neoplasm / Q000032:analysis; D004961:Estramustine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D010783:Photometry; D011471:Prostatic Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000473:pathology
chemical_list: D004273:DNA, Neoplasm; D009588:Nitrogen Mustard Compounds; D004961:Estramustine